Jesse M. Tettero

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Rethinking intensive salvage therapy in the venetoclax era.

Rethinking intensive salvage therapy in the venetoclax era.

Journal: Haematologica
Published: August 09, 2026

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Journal: HemaSphere
Published: February 26, 2026

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Journal: HemaSphere
Published: February 23, 2026

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis.

Journal: Haematologica
Published: February 20, 2026

Genomics of Acute Myeloid Leukemia at Diagnosis and Remission.

Genomics of Acute Myeloid Leukemia at Diagnosis and Remission.

Journal: medRxiv : the preprint server for health sciences
Published: December 17, 2025

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.

Journal: Leukemia
Published: October 20, 2025

Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.

Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.

Journal: Leukemia
Published: August 05, 2025

Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.

Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.

Journal: Leukemia
Published: July 24, 2025

Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes.

Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes.

Journal: Advances in experimental medicine and biology
Published: June 09, 2025

Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications.

Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications.

Journal: Seminars in hematology
Published: June 06, 2025

Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.

Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.

Journal: Haematologica
Published: December 02, 2024

Acute myeloid leukemia: does sex matter?

Acute myeloid leukemia: does sex matter?

Journal: Leukemia
Published: August 30, 2024
Showing 1-12 of 28

Last Updated: 09/26/2026